AdipoGen Life Sciences

Efavirenz

CHF 50.00

In stock

AG-CR1-3751-M01010 mgCHF 50.00

AG-CR1-3751-M05050 mgCHF 140.00

AG-CR1-3751-M250250 mgCHF 320.00

More Information
Product Details
Synonyms	DMP 266; EFV; L-743,726
Product Type	Chemical
Properties
Formula	C₁₄H₉ClF₃NO₂
MW	315.7
CAS	154598-52-4
RTECS	DM3440000
Purity Chemicals	≥98% (HPLC)
Appearance	White to off-white solid.
Solubility	Soluble in DMSO (25mg/ml), DMF (20mg/ml) or ethanol (10mg/ml). Insoluble in water.
Identity	Determined by ¹H-NMR.
InChi Key	XPOQHMRABVBWPR-UHFFFAOYSA-N
Smiles	ClC1=CC=C2C([C@@](C#CC3CC3)(C(F)(F)F)OC(N2)=O)=C1
Shipping and Handling
Shipping	AMBIENT
Short Term Storage	+4°C
Long Term Storage	-20°C
Handling Advice	Keep cool and dry.
Use/Stability	Stable for at least 2 years after receipt when stored at -20°C.
Documents
MSDS	Download PDF
Product Specification Sheet
Datasheet	Download PDF

Description

Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that exhibits antiviral and anticancer activities.
Efavirenz binds to wild-type and mutant HIV-1 RTs (Ki= 2.93nM and 3.85-56.5nM, respectively). It inhibits wild-type and mutant HIV-1 viral replication in MT-4 human T lymphoid cells (IC95s = 1.5-1,500 nM). Efavirenz also prevents RNA plus-strand initiation with an IC₅₀ value of 17nM.
Efavirenz is an anti-HIV drug, commonly used in combination therapy for AIDS treatment. It is part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1.
In various cancer cell lines, Efavirenz inhibits cellular proliferation and increases activation of p53.
CARD8 inflammasome senses HIV-1 protease activity. In HIV-infected cells, CARD8 cannot detect the virus because the viral protease remains inactive as a subunit of unprocessed Gag-Pol polyprotein. HIV-1-specific non-nucleoside reverse transcriptase inhibitors (NNRTIs), such us Efavirenz, can trigger CARD8 sensing because they bind to HIV-1 Pol and enhance intracellular Gag-Pol polyprotein dimerization, which causes premature viral protease activation. Treating HIV-1-infected macrophages and CD4+ T cells with NNRTIs leads to CARD8-mediated caspase-1 activation and pyroptotic cell death. Induction of the CARD8 inflammasome activation has led to rapid clearance of latent HIV-1 in patient CD4+ T cells after virus reactivation.

Product References

L-743,726 (DMP-266): A novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase: S.D. Young, et al.; Antimicrob. Agents Chemother. 39, 2602 (1995)
The nonnucleoside reverse transcriptase inhibitors efavirenz and nevirapine in the treatment of HIV: M. Sheran; HIV Clin. Trials 6, 158 (2005)
HIV-susceptible transgenic rats allow rapid preclinical testing of antiviral compounds targeting virus entry or reverse transcription: C. Goffinet, et al.; PNAS 104, 1015 (2007)
HIV-1 reverse transcriptase plus-strand initiation exhibits preferential sensitivity to non-nucleoside reverse transcriptase inhibitors in vitro: J.A. Grobler, et al.; J. Biol. Chem. 282, 8005 (2007)
Efavirenz in the therapy of HIV infection: N.Y. Rakhmanina & J.N. van den Anker; Expert Opin. Drug Metab. Toxicol. 6, 95 (2010)
Cytotoxic effect of efavirenz is selective against cancer cells and associated with the cannabinoid system: M. Hecht, et al.; AIDS 27, 2031 (2013)
Efavirenz induces neuronal autophagy and mitochondrial alterations: P.R. Purnell & H.S. Fox; J. Pharmacol. Exp. Ther. 351, 250 (2014)
Mechanism of allosteric inhibition of HIV-1 reverse transcriptase revealed by single-molecule and ensemble fluorescence: G.D. Schauer, et al.; Nucleic Acids Res. 42, 11687 (2015)
CARD8 is an inflammasome sensor for HIV-1 protease activity: Q. Wang, et al.; Science 371, 6535 (2021)

Call	+41 61 926 6040
Fax	+41 61 926 6049